These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 26036636

  • 1. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
    Zheng YZ, Wang L, Hu X, Shao ZM.
    Oncotarget; 2015 Sep 08; 6(26):22985-95. PubMed ID: 26036636
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, Wang M, Yi Z, Li H, Li H, Ren G.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918160. PubMed ID: 31899528
    [Abstract] [Full Text] [Related]

  • 4. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A, Noorbakhsh A, Tokin C, Chang D, Blair SL.
    Ann Surg Oncol; 2013 Oct 03; 20(10):3274-8. PubMed ID: 23838924
    [Abstract] [Full Text] [Related]

  • 5. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.
    Wo JY, Chen K, Neville BA, Lin NU, Punglia RS.
    J Clin Oncol; 2011 Jul 01; 29(19):2619-27. PubMed ID: 21606424
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
    Wang C, Zhou Y, Zhu H, Huang W, Chen Z, Mao F, Lin Y, Zhang X, Shen S, Zhong Y, Li Y, Sun Q.
    Cancer Med; 2018 Nov 01; 7(11):5420-5430. PubMed ID: 30277006
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL, Zhang JX, Fu DY.
    World J Surg Oncol; 2018 Dec 17; 16(1):236. PubMed ID: 30558615
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term prognostic effect of hormone receptor subtype on breast cancer.
    Hwang KT, Kim J, Jung J, Kim BH, Park JH, Jeon SY, Hwang KR, Roh EY, Park JH, Kim SJ.
    Breast Cancer Res Treat; 2020 Jan 17; 179(1):139-151. PubMed ID: 31595365
    [Abstract] [Full Text] [Related]

  • 18. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E.
    Arch Iran Med; 2016 Oct 17; 19(10):680-686. PubMed ID: 27743431
    [Abstract] [Full Text] [Related]

  • 19. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC, Rastogi P, Geyer CE, Miller LD, Thomas A.
    Oncologist; 2018 Apr 17; 23(4):481-488. PubMed ID: 29330212
    [Abstract] [Full Text] [Related]

  • 20. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.
    Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA.
    J Clin Oncol; 2001 Jan 01; 19(1):18-27. PubMed ID: 11134191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.